0001636282-26-000119.txt : 20261002 0001636282-26-000119.hdr.sgml : 20261002 20261002213015 ACCESSION NUMBER: 0001636282-26-000119 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20261001 FILED AS OF DATE: 20261002 DATE AS OF CHANGE: 20261002 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: King-Jones Heidy CENTRAL INDEX KEY: 0001794898 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37722 FILM NUMBER: 261438621 MAIL ADDRESS: STREET 1: C/O SPYRE THERAPEUTICS, INC. STREET 2: 221 CRESCENT STREET, BLDG 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Spyre Therapeutics, Inc. CENTRAL INDEX KEY: 0001636282 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 464312787 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 6176515940 MAIL ADDRESS: STREET 1: 221 CRESCENT STREET STREET 2: BUILDING 23, SUITE 105 CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: Aeglea BioTherapeutics, Inc. DATE OF NAME CHANGE: 20150311 4 1 wk-form4_1790991012.xml FORM 4 X0609 4 2026-10-01 0 0001636282 Spyre Therapeutics, Inc. SYRE 0001794898 King-Jones Heidy false 221 CRESCENT STREET, BUILDING 23, SUITE 105 WALTHAM MA 02453 0 1 0 0 See Remarks 1 Common Stock 2026-10-01 4 M 0 28933 14.50 A 31778 D Common Stock 2026-10-01 4 S 0 400 89.24 D 31378 D Common Stock 2026-10-01 4 S 0 16605 90.35 D 14773 D Common Stock 2026-10-01 4 S 0 7228 91.35 D 7545 D Common Stock 2026-10-01 4 S 0 2100 92.70 D 5445 D Common Stock 2026-10-01 4 S 0 2600 93.46 D 2845 D Stock Option (Right to Buy) 14.50 2026-10-01 4 M 0 28933 0 D 2033-09-01 Common Stock 28933 482478 D This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $88.63 to $89.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $89.96 to $90.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $91.10 to $92.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $92.12 to $93.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $93.17 to $93.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer. Chief Legal Officer and Corporate Secretary /s/ Heidy King-Jones 2026-10-02